Innovation Pharm (IPIX) had the dose escalation wr

Innovation Pharm (IPIX) had the dose escalation written into the protocol for their novel human defensin mimetic antiviral/anti-inflammatory/antibiotic drug brilacidin. If FDA pushed back on 4 doses of LL due to safety, I imagine we could have done the same: start at 2 doses, prove it's safe, then go to 4 or more, or even IV. Might have taken a little while longer for statistical power with more subjects needed for CD12, but it could have saved CD16 trial possibly. But really, the past is the past. Hopefully we are able to satisfy FDA in the here and now. EUA and/or start CD16 soon.